➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Merck
Moodys
Harvard Business School
Boehringer Ingelheim
Express Scripts

Last Updated: September 25, 2020

DrugPatentWatch Database Preview

Litigation Details for In re: Sensipar (Cinacalcet Hydrochloride Tablets) Antitrust Litigation (D. Del. 2019)

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

In re: Sensipar (Cinacalcet Hydrochloride Tablets) Antitrust Litigation (D. Del. 2019)

Docket   Start Trial Date Filed 2019-07-31
Court District Court, D. Delaware Date Terminated
Cause 15:1 Antitrust Litigation Assigned To Leonard Philip Stark
Jury Demand Plaintiff Referred To
Parties ACTAVIS INC.; ACTAVIS PHARMA INC.; ACTAVIS PLC; AMGEN INC.; CESAR CASTILLO, INC.; CIPLA LTD.; CIPLA USA, INC.; CLERK OF MDL PANEL; IN RE: SENSIPAR (CINACALCET HYDROCHLORIDE TABLETS) ANTITRUST LITIGATION; KPH HEALTHCARE SERVICES, INC.; TEAMSTERS LOCAL 237 RETIREES' BENEFIT FUND; TEAMSTERS LOCAL 237 WELFARE FUND; TEVA PHARMACEUTICAL INDUSTRIES LTD; TEVA PHARMACEUTICALS USA, INC.; UFCW LOCAL 1500 WELFARE FUND; WATSON LABORATORIES, INC.; WATSON PHARMACEUTICALS, INC.
Patents 6,011,068; 6,211,244; 7,829,595; 9,375,405
Attorneys Adam J. Pessin; Ashley E. Johnson; Bart D. Cohen; Benjamin F. Johns; Bradley J. Vettraino; Brent Landau; Brian E. Farnan; Brian P. Egan; Clerk of MDL Panel; David E. Lansky; David M. Fry; Deanne K. Cevasco; Dianne M. Nast; Dina R. Hoffer; Donna M. Evans; Eric J. Stock; Gregory Asciolla; Henninger S. Bullock; Hugh D. Sandler; Ian Connor Bifferato; Irving Scher; Jack B. Blumenfeld; James W. Dabney; Jay L. Himes; Jayne A. Goldstein; Jeffrey S. Istvan; John W. Shaw; JOSEPH J. DEPALMA; Karen Elizabeth Keller; Karen W. Lin; Karin E. Garvey; Lee Albert; Linda P. Nussbaum; Lynn M. Russo; Matthew J. Perez; MELANIE L. KATSUR; Melinda R. Coolidge; Michael J. Farnan; Michael M. Buchman; Michelle C. Clerkin; Ned C. Weinberger; Patrice P. Jean; Paul Costa; Richard A. Spehr; Robert J. Kriner , Jr.; Roberta D. Liebenberg; Robin A. van der Meulen; Scott M. Tucker; Sharon K. Robertson; Sue L. Robinson; Thomas M. Sobol; Tiffany Joanne Cramer; Vera Gerrit Belger
Firms Chimicles Schwartz Kriner & Donaldson-Smith LLP; Farnan LLP; Gibson, Dunn & Crutcher, LLP; Labaton Sucharow LLP; Lite, Depalma, Greenberg, LLC; Morris, Nichols, Arsht & Tunnell; Nastlaw LLC; Shaw Keller LLP; The Bifferato Firm, P.A.; United States Judicial Panel on Multidistrict Litigation, Thurgood Marshall Federal Judiciary Buildi
Link to Docket External link to docket
Small Molecule Drugs cited in In re: Sensipar (Cinacalcet Hydrochloride Tablets) Antitrust Litigation
The small molecule drug covered by the patents cited in this case is   Start Trial .
Biologic Drugs cited in In re: Sensipar (Cinacalcet Hydrochloride Tablets) Antitrust Litigation
The biologic drug covered by the patents cited in this case is   Start Trial .

Details for In re: Sensipar (Cinacalcet Hydrochloride Tablets) Antitrust Litigation (D. Del. 2019)

Date Filed Document No. Description Snippet Link To Document
2019-09-20 16 Redacted Document the ’068 patent”) and 9,375,405 (“the ’405 patent”), which expired on March 8, 2018 and September 22,… 12 Abstract, United States Patent No. 9,375,405. …the ’068 patent and certain other patents (collectively, the “NPS Patents”). The NPS Patents relate to…certifications against the patents covering Sensipar. Among these patents were U.S. Patent Nos. 6,011,068 (the…’405 Patent 31. The U.S. Patent and Trademark Office (“PTO”) issued the ’405 patent in 2016 External link to document
2020-07-23 160 Redacted Document .) However, Amgen also owns U.S. Patent No. 9,375,405 (“ʼ405 patent”), which is listed in the Orange … The patent covering the cinacalcet drug substance, U.S. Patent No. 6,011,068 (“ʼ068 patent”), expired…ʼ405 (formulation) patent, i.e., the generic manufacturers asserted that the patent was invalid, unenforceable…claims but would lose if the patent litigation were to continue and the patent were held invalid or not … not involve the assertion of patent rights or the settlement of patent ligation. Actavis, in contrast External link to document
2019-09-20 17 Redacted Document Amgen’s drug substance patent – U.S. Patent No. 6,011,068 (“the ’068 Patent”) – expired on March 8, … 2016); 6,313,146 (expiry December 14, 2016); 6,011,068 19 Protecting Consumer Access …068 patent, ’003 patent, ’244 patent,’146 patent, and ’884 patent (collectively, the “NPS Patents”). …obtained a new patent purportedly covering Sensipar, U.S. Patent No. 9,375,405 (“the ’405 patent”). This patent…and the ’405 patent (issued June 28, 2016) from those patents’ inventors. The ’405 patent is a formulation External link to document
2019-10-22 57 Notice of Service 884 Patent); 6,031,003 (the ’003 Patent); 6,313,146 (the ’146 Patent); 6,011,068 (the ’068 Patent); 7,829,595… “The NPS Patents” means collectively U.S. Patent Nos. 6,211,244 (the ’244 Patent); 6,001,884 (the…7,829,595 (the ’595 Patent); and 9,375,405 (the ’405 Patent). G. “Sensipar Patent Litigation” means…any NPS Patents and related conduct in the prosecution of the underlying patent applications…listing of any NPS Patents in the FDA’s Orange Book; c. institution of any patent infringement External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Express Scripts
Merck
Boehringer Ingelheim
Medtronic
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.